Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,472 total articles
Limbach's shift toward Owner Direct Relationships, solid free cash flow and a reasonable valuation leave the stock underappreciated after a volatile 52-week range. I’m upgrading to a long swing trade with a $65 target over the next 45 trading days, a $49.86 entry and a $44 stop — a plan sized for a medium-risk trader.
Lockheed Martin (LMT) sits in the sweet spot of elevated defense spending and renewed missile demand, backed by a reported $230B backlog. Fundamentals and cash flow support a measured long trade, but elevated leverage, program execution risk, and short-term technical weakness argue for a tight stop and staged exposure.
Lockheed Martin's stock pulled back sharply on profit-taking, creating a tactical buying opportunity. The company sits on a record ~$230B backlog, generates roughly $8.7B in free cash flow, and trades at a reasonable P/E (~19x) given its defense exposure and dividend yield (~2.6%). Technicals show oversold conditions and compressed short interest d…
Grab reported solid Q2 results, raised full-year guidance, and is trading well below its 52-week high with improving profitability. We lay out an actionable long trade with entry at $3.44, a stop at $3.00 and a $5.20 target over a 180-trading-day horizon while highlighting the key catalysts and risks investors must watch.
Zeta Global reported another beat-and-raise quarter with revenues of $442.8M (up 43.5% YoY) and raised 2026 revenue guidance to roughly $1.82B. With AI adoption accelerating among its largest customers and free cash flow now meaningful, ZETA looks set to re-rate as growth proves durable. This trade idea lays out an actionable long entry, risk contr…
<p>PepsiCo (PEP) has pulled back to $137.75 after a messy 2026 where Coca-Cola outperformed. The company still generates roughly $9.3B in free cash flow and yields ~4.2% on the dividend, supporting a buy-the-dip trade. That said, higher leverage, margin pressure and a premium consumer brand battle mean this is a patient trade - expect volatility an…
Nvidia's announced $279 billion strategic investment reshapes its addressable market, accelerating data-center spend, ecosystem lock-in, and recurring revenue potential. The move increases execution risk but creates a compelling asymmetric reward for a well-sized long. Entry $900, stop $700, target $1400, horizon 180 trading days.
SSR Mining just converted a troubled asset into liquidity and returned capital optionality to shareholders. With zero debt, roughly $7.07 cash per share, $347M of recent free cash flow and a market cap near $7.6B, the stock looks cheap relative to its operational cash generation and optionality from buybacks. This trade lays out a concrete entry, s…
Credo's recent pullback priced in margin noise and dilution concerns, but the company is riding structural AI data-center tailwinds that could sustain outsized revenue growth. At current levels the market is punishing cyclicality and concentration more than fundamentals warrant. This trade idea lays out an entry at $168.00, a stop at $140.00 and a …
Star Group (SGU) checks a lot of boxes for income and value investors: a 6%+ yield, 14 consecutive years of annual distribution increases, positive free cash flow of roughly $56.8M and a sub-$600M enterprise value. With a P/E near 5.2 and EV/EBITDA ~3.2, SGU looks priced for cyclical weakness rather than the steady, regulated-like cash flow its res…
Bloom Energy (BE) just had another catalyst that sent the stock sharply higher. With guidance lifted, a growing $20B backlog narrative, and clear AI data-center demand, the trade is to buy on a disciplined pullback. Entry $250.00, stop $220.00, target $340.00, horizon: long term (180 trading days).
Par Pacific (PARR) looks like a cheap, high-cash-flow refining play after a strong set of results and balance-sheet repair. This is a tactical long: ride remaining margin strength while protecting against a snap-back in fuel spreads. Entry $81.32, stop $72.00, target $100.00. Time the trade for the long-term window (180 trading days) with a mid-ter…
Innodata (INOD) has re-emerged as one of the cleaner pure plays in data-engineering for AI: accelerating revenue, wider gross margins and large new contract wins underpin an upgraded long stance. The stock is expensive today at $55.64, but the company’s 40%+ guidance and a 49% adjusted gross margin show the story is moving from promise to proof. Th…
Oracle is down roughly 55% from its 2025 highs and trading at $159.70 after a period of heavy data-center spending that pushed free cash flow negative. Fundamentals remain solid - 17% revenue growth to ~$67B, 36% net income growth, and 75% cloud infrastructure growth - while valuation metrics (P/E ~27, EV/EBITDA ~17.5) look reasonable for a busines…
Rocket Companies (RKT) is trading near $14 and looks attractive as a mid-term trade. Market-share gains across direct and partner channels, activist interest and a clear path to cost and cross-sell synergies support upside to $18 over the next 45 trading days, while a $12.10 stop limits downside if housing stress re-intensifies.
Nano Labs (NA) is a micro-cap semiconductor and distributed computing play that combines chip design, AI hardware and a meaningful crypto treasury. With a market cap of roughly $51.3M and a 70,000 BNB reserve, the company offers an asymmetric payoff: a successful execution of its AI-Web3 strategy or a rebound in BNB could re-rate the stock, while c…
Bristol Myers Squibb is trading near its 52-week high after sustained strength in newer franchises, notably Camzyos, which grew 74% YoY to $729M in H1 2026. Fundamentals - including a $136.5B market cap, $11.44B free cash flow and a 3.76% dividend yield - and improving technicals argue for a mid-term long. This trade lays out an entry at $66.80, st…
Qualcomm is a high-quality semiconductor franchise trading at a reasonable multiple with strong cash generation and a credible pathway into AI and PCs. The trade is a long-term buy for investors willing to accept near-term handset weakness and execution risk on data-center ambitions. Entry, stop and target provided for a 180-trading-day horizon.
AST SpaceMobile is a speculative long with a concrete catalyst schedule. I’m initiating a long position at $62.30 with a $92 target and a $48 stop, banking on the company converting carrier partnerships and a planned constellation deployment in early 2027 to accelerate revenue and compress an extreme valuation.
Hershey has weathered a commodity storm and kept pricing power intact. With cocoa moving lower, margin recovery is realistic, consensus EPS growth still elevated, and the shares offer a 3.31% cash yield. Technicals look oversold and short interest remains elevated — conditions that favor a measured long. Trade plan included for mid-term (45 trading…
Interactive Brokers (IBKR) is benefiting from strong account growth, rising DARTs and a 49% surge in margin loans, but it trades at a premium multiple and shows short-term technical fatigue. The trade: selectively buy weakness around $86.00 with a $105.00 target over a mid-term 45 trading day horizon and a $79.00 stop. Risk/reward is asymmetric if …
Northwest Natural (NWN) is a compact, dividend-rich regulated gas and water distributor that offers a 4%+ yield, reasonable valuation and visible catalysts (rate cases, acquisitions, RNG growth). The business has predictable cash flows and a long history of dividend increases; the main near-term concerns are leverage and negative free cash flow. Th…
Micron is trading around $1,015 after a sharp multi-month run. Fundamentals support further gains: $1.15T market cap, $44.69 EPS, strong ROE and $26.2B in free cash flow. This trade idea lays out an actionable long with entry, stop and target for a long-term (180 trading days) horizon while calling out the main risks, including Chinese competition …
BioAge (BIOA) is a clinical-stage biotech with an oral NLRP3 inhibitor, BGE-102, showing strong Phase 1 biomarker moves. Topline Phase 2 cardiovascular risk data are due in H2 2026. The stock is trading at $9.59 with a market cap of ~$440M and cash runway into 2029. This trade targets a rebound into the low teens and beyond if Phase 2 confirms the …
CGI (GIB) trades on a reasonable multiple with buyback-driven EPS support and a manageable technical setup. Enter a mid-term long to capture a rebound toward the $86 level while limiting downside with a $68 stop. Watch for buyback commentary and quarterly results to confirm the thesis.
